EU/3/18/2066:

pemigatinib

Overview

On 24 August 2018, orphan designation (EU/3/18/2066) was granted by the European Commission to Incyte Biosciences Distribution B.V., the Netherlands, for pemigatinib for the treatment of biliary tract cancer.

Pemigatinib has been authorised in the EU as Pemazyre since 26 March 2021.

Key facts

Active substance
pemigatinib
Intented use
Treatment of biliary tract cancer
Date of designation
24/08/2018
Orphan designation status
Positive
EU designation number
EU/3/18/2066

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Pemazyre at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF icon orphan medicine assessment report .

Sponsor's contact details

Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
Noord-Holland
The Netherlands
E-mail: globalmedinfo@incyte.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

Related content

How useful was this page?

Add your rating